Feedback / Questions
hydrogen sulfide-releasing derivative of ketoprofen (ATB-352) - Antibe
https://www.businesswire.com/news/home/20220214005249/en/Antibe-Therapeutics-Reports-Q3-2022-Interim-Financial-and-Operating-Results
Feb 14, 2022
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Prev
Next